Challenges in optimizing EU market access for immuno-oncology therapies

24 September 2018
2019_biotech_test_vial_discovery_big

With CAR-T therapies closer than ever to delivering on their promise but still facing significant obstacles, Eva Marchese (pictured above) and Cécile Matthews from Charles River Associates provide an Expert View on the topic.

Since the approval of Yervoy (ipilimumab) in 2011 for the treatment of melanoma, the idea of mobilizing a patient’s immune system to combat a wide range of cancers has been transformed from a promising concept to an emerging standard for oncology therapies.

Today, there are several approved immuno-oncology (I-O) products on the market and many more in clinical development – including monoclonal antibody treatments that target specific immune checkpoint receptors such as programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand (PD-L1).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology